SYNGENE - Swing Trade Analysis with AI Signals
← Back to ListKey Parameters
⭐ Swing Trade Rating: 3.2
✅ Positive
The company has a strong recent PAT growth of 11.4 Cr. this quarter compared to the previous quarter’s 154 Cr., indicating operational improvements. Furthermore, its debt-to-equity ratio of 0.04 suggests a conservative financial structure.
⚠️ Limitation
Recent downgrades from MarketsMojo and SimplyWall.st suggest deteriorating fundamentals and a ‘Strong Sell’ rating, which signals substantial downside risk for the stock. The significant decline in PAT (Qtr) (-84.6%) also raises concerns about profitability.
📉 Company Negative News
Analysts have lowered their forecasts following a surprise loss reported by Syngene International, and the company has been downgraded to 'Average Quality' and ‘Strong Sell’ ratings due to declining fundamentals and technical metrics.
📈 Company Positive News
None found
🏭 Industry
The biotechnology industry is typically characterized by high growth potential but also significant volatility driven by R&D breakthroughs, regulatory approvals, and competitive pressures. Biopharmaceutical companies like Syngene are often reliant on contracts with larger pharmaceutical firms.
🧾 Conclusion
Given the recent negative news and downgrades, an entry price of 375 ₹ would be a cautiously optimistic approach, aiming to capitalize on potential recovery if fundamentals stabilize. Exit guidance is at 497 ₹ (DMA 200) or 426₹ (DMA 50), representing key support levels that could signal a reversal. Overall, the stock presents a moderate swing trading opportunity due to short-term volatility and uncertain future prospects.